Daewoong Pharmaceutical Co., Ltd. Announces Positive Safety Review for Bersiporocin
Daewoong Pharmaceutical announced that its idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin received a recommendation to continue its global Phase 2 clinical trial.
The third Independent Data Monitoring Committee (IDMC) review confirmed the safety and continuation of the study, with 94 patients enrolled out of 102 planned across Korea and the U.S.
The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns that would impact the trial's continuation.
- 94 participants enrolled, representing approximately 92% of the target population (102 patients)
- The study is progressing as planned
Author's summary: Daewoong's Bersiporocin continues global Phase 2 trial.
More News
- In Anish Kapoor’s Hands, an Offshore Gas Rig Became a Call for Climate Accountability
- Political agenda in the presentation of student demands
- Cruelty and the human face of evil
- Lisbon’s Viral Pastel de Nata Is a Gift and a Curse
- Lafayette Mardi Gras Parade Route Returning to Jefferson St. in Downtown Lafayette
- Italian Fascists’ Love Affair With Israel Started Long Before Giorgia Meloni | Novara Media
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Importing beef is not the solution | GABEL
- 400,000 Coloradans have cast votes so far
- Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age | PharmExec